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ScienceDirectThe deeply intertwined evolutionary history between
bacteriophages and bacteria has endowed phages with highly
specific mechanisms to hijack bacterial cell metabolism for
their propagation. Here, we present a comprehensive, phage-
driven strategy to reveal novel antibacterial targets by the
exploitation of phage-bacteria interactions. This strategy will
enable the design of small molecules, which mimic the
inhibitory phage proteins, and allow the subsequent hit-to-lead
development of these antimicrobial compounds. This
proposed small molecule approach is distinct from phage
therapy and phage enzyme-based antimicrobials and may
produce a more sustainable generation of new antibiotics that
exploit novel bacterial targets and act in a pathogen-specific
manner.
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The current limitations of antibiotic
development threaten our long-term capacity
to treat bacterial infections
Since their discovery in 1928 and development for clinical
use in the 1940s, antibiotics have saved millions of lives and
are deeply ingrained in countless important medical pro-
cedures. Unfortunately, antibacterial drug resistance
among clinically important pathogens is increasing towww.sciencedirect.com dangerous levels worldwide and jeopardize the efficacy
of clinical treatments [1]. Over the past twenty years, only a
few new classes of antibiotics have been discovered and
approved for clinical trials [2]. Primarily, small and
medium-sized enterprises carry out antibacterial develop-
ment, often using a traditional R&D strategy based on
chemical modification of existing molecules [3]. The cur-
rent clinical development pipelines for antibiotics mainly
focus on the combinations of known antibiotics and that
remain as the principal to limit the development of antibi-
otic resistance [4]. Therefore, only a limited number of
antibacterial targets are being exploited. As of July 2020,
among 45 new antibiotics in the clinical development only
eleven belong to a novel class, targeting primarily Gram-
positive bacteria (The Pew Charitable Trusts; URL:
https://www.pewtrusts.org/en/research-and-analysis/
data-visualizations/2014/antibiotics-currently-in-clinical-
development). Most antibiotics have broad spectra of
activity against various bacterial species, not only exacer-
bating the development of resistance if used inappropri-
ately [5], but also having a negative impact on commensal
bacteria, for example, the gut microbiota [6].
To date, the number of targets exploited by commercial
antibacterial agents is estimated around 40 [3]. However,
with the development of ‘omics’ technologies, numerous
novel modes of action and an unprecedented number of
bacterial cell structures could potentially be exploited,
even using uncharacterised antimicrobial agents [7].
Therefore, there is an urgent need to accelerate the
development of new antimicrobial agents and to identify
novel antibacterial targets that are less prone to resistance
development and act in a more specific way. In this
review we explore the untapped potential of bacterio-
phages in this area with an expanded strategy for small-
molecule development.
The interaction between bacteriophages and
bacteria driven by their deeply entangled
co-evolutionary histories
Throughout evolution, bacteriophages continuously
adapt to confront their bacterial hosts in an arms-race
during the lytic infection cycle. Phages use sophisticated
molecular mechanisms to hijack the bacterial cell metab-
olism for the production of progeny viral particles [8,9].
This closely intertwined relationship has led to the emer-
gence of highly specific and evolution-optimised molec-
ular interactions [10,11] and therefore represents aCurrent Opinion in Biotechnology 2021, 68:1–7
2 Nanobiotechnology – phage therapyunique source to identify new potential antibacterial
targets.
Following the advancements in high-throughput genome
sequencing, tens of thousands of phage genomes have
been sequenced. Ranging from 2.3 kb to 735 kb in
genome size [12,13], phages encode precise information
to alter DNA replication, RNA transcription, cell division,
and protein translation pathways in the host bacteria [10].
However, due to the absence of homology to known
proteins and the lagging in experimental evidence,
approximately half to two thirds of the phage gene
products have merely been annotated as hypothetical
proteins of unknown function [14]. Most of these hypo-
thetical proteins are expressed during the early stages of
phage infection [15–17], which indicates their importance
in host metabolism takeover. Looking into the functions
of these hypothetical phage proteins, especially those
with detrimental effect towards host growth, would not
only reveal detailed phage biology insights but, perhaps
more importantly, also understand bacterial reprogram-
ming during phage infection.
Phage-inspired antibacterial target discovery
Revealing new bacterial targets from phage researches
can inspire the screen and design of new small molecular
compounds, which mimic the growth-inhibitory effects of
the phage proteins. A key example of phage-derived
antibacterial discovery was first described in 2004. From
the genomes of 26 Staphylococcus aureus phages, Liu et al.
[18] found that 31 polypeptide families showed toxicity
towards the host when expressed in S. aureus. One of such
gene products, ORF104 from S. aureus phage 77, interacts
with helicase loader (DnaI), an essential protein in host
DNA replication. As a novel target, the interaction
between DnaI and ORF104 was subsequently used in
time-resolved fluorescence energy transfer (TR-FRET)
to screen for small molecules inhibitors. In the end, 36 out
of 125 000 screened commercial small molecules could
interrupt the molecular interaction between DnaI and
ORF104, and 11 were directly active against S. aureus at
reasonable MIC (16 mg/ml).
Expanding phage-inspired target discovery by
informed functional insights
Although the approach proposed by Liu et al. [18] was
focused on S. aureus and set for blind screening of phage
proteins and subsequent small molecules, its principle has
inspired researchers to look for novel molecular targets
from phages [19]. Beyond Gram-positive S. aureus, this
screening technique has been applied to Rhodococcus equi
[20], Mycobacterium smegmatis [21], and Gram-negative
pathogens including Escherichia coli [22], Pseudomonas
aeruginosa [23–25], Yersinia enterocolitica [26] and Klebsiella
pneumoniae [27]. In our own research, we aim to expand
this original phage-based target discovery strategy to
identify and to exploit novel antibacterial targets for drugCurrent Opinion in Biotechnology 2021, 68:1–7 discovery in a more comprehensive manner. This strategy
is driven by two complementary approaches: the ‘phage
genome-driven screening’ which starts from known toxic
phage proteins, leading to target discovery, and a
‘bacterial target-driven screening’ to identify phage-
encoded inhibitors against known presumptive bacterial
targets. Following confirmation of these interactions,
these approaches converge towards the design or screen
of small mimicking molecules for preclinical develop-
ment (Figure 1). These strategies are outlined and illus-
trated in the next sections.
Bacteriophage genome-driven screening
Because of the abundance of hypothetical proteins in
phage genome annotations, it is rational to search for
bactericidal polypeptides with novel targets among the
‘early’ hypothetical proteins of unknown function.
Advances in DNA sequencing technologies, protein
structure determination, and interaction modelling have
facilitated the screening process, and several systematic
methodologies have been developed. In this section, we
compare genomic screenings inspired by the study of Liu
et al. [18] and explore more optimised approaches for
target discovery.
Selecting phage material for genomic screening
Screening individual hypothetical genes from phage gen-
omes is a time consuming and laborious process. There-
fore, thoughtful selection of the test pool can reduce
efforts and maximise the efficiency to identify antibacte-
rial phage proteins. Apart from eliminating the genes
encoding proteins of known function (including structural
proteins) and proteins with predicted transmembrane
domains, focusing on small and early genes has signifi-
cantly reduced the work load in the screening of phage
genes [23,24,26]. Indeed, most reported phage-host inter-
actions occur at early stage upon infection and involve
small (250 amino acids) phage proteins [28]. Alterna-
tively, libraries with random phage genome fragments
instead of individual genes can be used, skipping the
labour-intensive step of individual gene cloning. How-
ever, an additional step is required to identify the specific
gene in the fragment that attenuates the bacterial growth
[20,21]. In this way, besides specific phage proteins,
unpredicted bactericidal polypeptides can be identified
[21].
Identifying antibacterial phage proteins
To detect growth inhibition caused by hypothetical
phage proteins, high throughput methods are desirable
to shorten the screening process. As such, we recently
developed a screening method based on high throughput
sequencing. After eliminating phage-particle associated
proteins with LC–MS/MS, all ‘true’ hypothetical phage
gene fragments were ligated to a high-copy vector
pU11L4 for transformation and sequencing using Illu-
mina HiSeq. Since ‘toxic’ gene products do not result inwww.sciencedirect.com
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Phage-based target discovery and its exploitation in the development of novel antibacterials. Two complementary yet integrated approaches are
proposed: 1) ‘phage genome-driven screening’ searches for antibacterial gene products within sequenced bacteriophage genomes. These
bactericidal phage proteins are used as baits to identify their interaction partners in bacterial cells. 2) ‘target-driven screening’ uses promising
essential bacterial protein complexes as targets to identify interacting phage proteins which inhibit the target. In a next step, these phage-host
interactions are characterised structurally and cross-validated. Finally, either a high-throughput screening assay can be developed to identify
antimicrobial small molecules against the phage-bacterial targets, or a structure-based approach can be applied up to rationally design phage
peptide-mimicking molecules. The resulting small molecules should also be tested for their antibacterial properties, cytotoxicity, solubility and
additional pharmacodynamic and pharmacokinetic properties as potential leads. ORF, open reading frame; ID, identification/identify; MS, mass
spectrometry; FRET, Förster/fluorescence resonance energy transfer; B2H, bacterial two-hybrid; Alpha-screen, amplified luminescent proximity
homogenous assay screen.viable recombinant plasmids for the cell, a negative
selection based on reduced sequencing depth for these
toxic loci is possible. Indeed, bactericidal polypeptides
can be pinpointed from these regions with low sequence
coverage depth (Figure 2, Kasurinen J, unpublished).
Although high-copy expression can efficiently identify
antibacterial phage proteins, false-positive results may
emerge due to overexpression-associated growth retarda-
tion. To avoid this problem, an integrative system based
on pUC18-mini-Tn7T-Lac vector compatible to gatewaywww.sciencedirect.com cloning system was applied to obtain single-copy, induc-
ible expression of hypothetical phage gene, optimized
with translational enhancers [23,24,29]. The inhibitory
effect caused by phage proteins can be identified using
either phage’s natural host or alternative bacterium such
as E. coli. The advantage of testing in E. coli roots in its
extensively available genetic tools, and is based on the
assumption that the target molecule is prevalent among
closely related bacteria [26,27]. Yet, since narrow-spec-
trum targets are often preferred for future antimicrobial
treatment [2,4,30], the identified antibacterial phageCurrent Opinion in Biotechnology 2021, 68:1–7
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Screening scheme based on high throughput sequencing to identify antibacterial phage proteins.proteins should be tested in multiple hosts to determine
the range of toxicity and conservation of the bacterial
target [21,23,24,31].
Identifying bacterial targets of antibacterial phage
proteins
Once antibacterial phage proteins are identified, they can
serve as a bait to discover antibacterial targets. This
identification of the bacterial interaction partner remains
a key aspect. For this, different techniques are available,
including pull-down followed by mass spectrometry
[18,31], yeast two-hybrid [24] and genome-based screens
that focus on abolishing the toxicity by either deleting
[22] or overexpressing [32] the target protein. Suitable
new targets for drug discovery should be absent in eukar-
yotes, conserved in (specific) bacteria, preferentially
essential for growth, and susceptible to the inhibition
by antibacterials. Moreover, the mechanism of inhibition
must be distinct from existing antibiotics to avoid cross-
resistance [33]. To date, the most promising protein
candidates include those impacting host replication
(the gene product Gp8 of phage N4 against E. coli
DNA polymerase HolA), transcription (Gp2 from E. coli
phage T7 against RNA polymerase RpoD), and cell
division machineries (T7’s Gp0.4 targeting the cell divi-
sion protein FtsZ) [19]. However, phage-host studies
reveal that much more key processes in the host are
targeted by phages [10].
Bacterial target-driven screening to identify
phage-encoded inhibitors
Unlike the phage genome-driven screening approach
where the screening process begins with massive genome
mining, target-driven screening uses defined essential
protein complexes in the host cells as baits to fish outCurrent Opinion in Biotechnology 2021, 68:1–7 unknown interaction partners from bacteriophages.
Meanwhile, this approach leads to the discovery and
analysis of mechanisms that govern these key bacterial
processes. In an early study by Van den Bossche et al. [25],
essential protein complexes involved in Pseudomonas
metabolism were selected as baits, including RpoA,
DnaN for transcription and genome replication, MvaT,
Hfq for transcriptional regulation, FtsZ for cell division,
AcpP for fatty acid biosynthesis, and GlcB for energy
maintenance. Mutant strains containing these tagged
protein complexes are infected by phage and subjected
to pull-down and downstream mass spectrometry. In this
analysis, 37 phage interaction partners were identified,
eight of which directly affected the bacterial growth [25].
Using a similar method, Klimuk et al. [34] identified RNA
polymerase subunit b’ (RpoC) interacting proteins,
Gp25.1 and Gp36 of Pseudomonas phages LUZ19 and
LKA1, respectively. Their functional equivalent in E.
coli phage T7 is Gp2, which stand-alone can inhibit the
function of host RNA polymerase [35]. Moreover, Dip/
Gp37 of Pseudomonas phage phiKZ, an RNA degrado-
some interacting protein, was found to bind the RNA
binding sites on the RNaseE component to reduce RNA
turnover [36]. Also, an inhibitor of transcriptional regu-
lator MvaT was identified from P. aeruginosa phage
LUZ24, Mip/Gp4, which prevents MvaT from binding
to foreign DNA and hence ensures the viral transcription
[24].
Mimicking the growth-inhibitory effect of
phage proteins
Bacterial proteins that are selectively inhibited by phage
polypeptides could potentially serve as novel antibacte-
rial targets, as their disruption could destabilise essential
processes and lead to growth retardation of the bacterium.www.sciencedirect.com
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as well as specification of the interaction site should be
performed to establish an efficient method to identify
small molecules or antimicrobial peptides that mimic the
antibacterial effect of the phage proteins [18,37]. More-
over, the experimental approach should be combined
with structural and biophysical analysis and interaction
modelling to enable a direct design of potent inhibitors
against the identified targets [38]. Structures of a handful
phage proteins targeting promising antibacterial targets
have been determined by high-resolution X-ray crystal-
lography [37,39], nuclear magnetic resonance (NMR)
[35,40] and cryo-electron microscopy (cryo-EM)
[41,42]. For example, two distinct proteins, Gam from
E. coli phage l and Orc/Gp0.3 from T7, were structurally
characterised via cryo-EM. Both were found mimicking
DNA and might be exploited for therapeutic inhibitors of
DNA binding proteins [41,42]. Similarly, via X-ray crys-
tallography, the Dip protein of phage phiKZ was found to
bind the RNA binding site [36], which may inspire the
discovery of therapeutic inhibitors of RNA turnover
[43,44]. Using NMR, Gp2 from E. coli phage T7 was
shown to alter the conformation of RNA polymerase, thus
restricting the access of ssDNA to the active site. This
inactivation represents an alternative mechanism to deac-
tivate bacterial RNA polymerase [35,45]. In addition,
Hood and Berger [37] further structurally and biochemi-
cally characterised the interaction between ORF104 of S.
aureus phage 77 and DnaI, the most promising interaction
from the initial screen by Liu et al. in 2004 [18], and
localised the interaction site to a small hydrophobic
pocket on the ATPase domain of the helicase loader
DnaI. Beyond designing small molecules that fit the
pocket of the active site, the in silico approach is also
able to optimise the hit compounds improving their
activity and calculating their physicochemical properties,
hence increasing the chance to successfully pass the
subsequent preclinical stage [38].
Conclusions and outlook
As ‘predators’ to bacterial pathogens, virulent phages
show great potential in the battle against antibiotic resis-
tance development. Most phages can only infect a very
limited range of bacterial isolates within a species. This
specificity stems from the long bacteria-phage evolution
and presents itself as a potentially sustainable solution
using phages as precision antibacterials especially against
drug-resistant ESKAPE pathogens. In addition to phage
therapy, where phage particles are applied at infected
sites, or enzyme-based antibacterials like lysins, under-
standing phage hijacking mechanisms can uncover
numerous novel targets either for existing antibacterial
drugs through new mode of action or for designing new
drugs.
It is noteworthy that, this field of research is still maturing
and faces challenges when expanded towards otherwww.sciencedirect.com emerging pathogens, as specific genetic tools must be
available, from expression vectors and efficient transfor-
mation to the ability for genome engineering. This strat-
egy also implies an extensive exploratory phase towards
the discovery and functional understanding of individual
phage-host interactions, which constitutes a long road of
fundamental research before exploitation is possible. In
addition, the interdisciplinary nature of the research
requires techniques ranging from microbial omics analy-
sis, functional and structural biochemistry to drug discov-
ery related bioinformatics and chemistry, which are very
challenging to integrate. However, considering the high
value of these evolution-optimised interactions, com-
pared to the randomness of current small molecule
screening, this extended development line could be
worth implementing.
Furthermore, recently emerging strategies exploiting
bacteriophages have extended beyond their original anti-
bacterial traits towards other alternative approaches. In
addition to the direct killing of the hosts, anti-virulent
agents may also be explored in phage research [46–49].
Pre-treatment with such compounds are likely to result in
a reduced virulence of the pathogen, making these bac-
teria more susceptible to phagocyte engulfment and
serum killing [46,49]. Therefore, the human immune
system becomes the essential third party in the battlefield
of phage and bacteria. This critical triangle thus becomes
the key towards both the development of sustainable
antimicrobials and understanding the biological and evo-
lutionary dynamic equilibrium between human and
microbiome.
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